SCHEMBL29978766

SCHEMBL29978766

COc1ccc(C(=O)O)c(-c2ccc(C3CC3)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.56
LTB4R Q15722 1/20 0.46
LTB4R2 Q9NPC1 1/20 0.46
KDM4E B2RXH2 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
DHODH Q02127 2/20 0.43
CYP2C8 P10632 1/20 0.43
AKR1C3 P42330 3/20 0.43
AKR1C2 P52895 3/20 0.43
MYC P01106 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
PRKAB2 O43741 2/20 0.41
PRKAG1 P54619 2/20 0.41
PRKAA2 P54646 2/20 0.41
PRKAA1 Q13131 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23354278 1.00 SMN1; SMN2 (0.56) SMN1; SMN2LTB4RLTB4R2KDM4ECYP1A2
SCHEMBL7591657 0.85 SMN1; SMN2 (0.75) SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL28860337 0.84 SMN1; SMN2 (0.41) SMN1; SMN2LTB4RLTB4R2CYP2C9ALDH1A1
SCHEMBL29979794 0.83 CYP2C9 (0.43) SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL23354249 0.83 CYP2C9 (0.43) SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL9151080 0.81 SMN1; SMN2 (0.64) SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL8566031 0.81 SMN1; SMN2 (0.64) SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL9683222 0.81 SMN1; SMN2 (0.64) SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL6701301 0.81 SMN1; SMN2 (0.63) SMN1; SMN2LTB4RLTB4R2KDM4ECYP1A2
SCHEMBL6778891 0.80 SMN1; SMN2 (0.62) SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 SMN1; SMN2 3850/4885LTB4R 1461/4885LTB4R2 1814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.